Browsing archives for September, 2018

NORML Supports Florida Voting Restoration Amendment

Generic 30 September 2018 | 0 Comments

NORML is pleased to support the grassroots Voting Restoration Amendment campaign in Florida, run by Second Chances Florida. Florida remains one of only four states with a lifetime ban on voting for people with past felony convictions, even after they have completed their full sentence – including any probation, parole, fines, and restitution. We at […]

Tagged in , , ,

Legalization: Is it Working?

Generic 29 September 2018 | 0 Comments

We as advocates of marijuana law reforms have never been in a better position than we are today to further our cause. Prior to states like Colorado, Washington, Oregon, Nevada, and others, legalizing and regulating marijuana, there was very little data to support our arguments to end marijuana prohibition. But, things have changed. So, is […]

Tagged in ,

Weekly Legislative Roundup 9/28/18

Generic 29 September 2018 | 0 Comments

Welcome to the latest edition of NORML’s Weekly Legislative Roundup! This week, the U.S. Drug Enforcement Administration placed CBD medication Epidiolex in Schedule V, the least restrictive category of the Controlled Substances Act. The move does not apply to CBD itself or other non-FDA-approved extracts containing it. U.S. Customs and Border Protection released an official […]

Tagged in , , ,

Teens who’ve tried marijuana have used it in more than one form

Did you know that? 28 September 2018 | 0 Comments

Most teens who’ve tried marijuana used it in more than one form, according to a new study, raising concerns about adolescent health amid a booming cannabis market.

DEA Reclassifies Plant-Derived Marijuana Medicine To Schedule V

Generic 28 September 2018 | 0 Comments

Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The US Food and Drug Administration had previously approved the product in June for the explicit treatment of two rare forms […]

Tagged in , , ,